Name: Latest research reports of Piramal Pharma Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Piramal Pharma Ltd.
Rating: 5
Author: ICICI Securities Limited

Piramal Pharma Ltd.

NSE: PPLPHARMA | BSE: 543635 | ISIN: INE0DK501011 | Industry: Pharmaceuticals
| Expensive Performer

219.0400 4.20 (1.95%)

NSE May 14, 2025 15:31 PM

28.86% Fall from 52W High

Volume: 3.5M

Piramal Pharma Ltd.

14 Nov 2022, 12:00AM

219.04

1.95%

Expect stronger H2 driven by CDMO

Buy: Piramal Pharma Ltd.

ICICI Securities Limited

Piramal Pharma’s (PPL) Q2FY23 performance was driven by growth across its business segments. Revenue grew 9.0% YoY (+16% QoQ) to Rs17.2bn.

Number of FII/FPI investors decreased from 266 to 257 in Mar 2025 qtr